top of page
What you need to know about new therapies for systemic sclerosis: A case-based approach
After attending this event, participants will be better able to;
Recognize 3 pathogenic mechanisms in systemic sclerosis;
Consider newer medications to target each pathogenic process;
Understand that further medications are under investigation.
Maggie Larché, MBChB, MRCP (UK), PhD
Professor, Department of Medicine, McMaster University
Director, Canadian Scleroderma Research Group
This initiative has been sponsored in part by Pfizer Canada through an educational grant.
bottom of page